PRPH vs. HOWL, NRXP, ELYM, CNTB, VNRX, GANX, FGEN, KRON, OTLK, and PRLD
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Werewolf Therapeutics (HOWL), NRx Pharmaceuticals (NRXP), Eliem Therapeutics (ELYM), Connect Biopharma (CNTB), VolitionRx (VNRX), Gain Therapeutics (GANX), FibroGen (FGEN), Kronos Bio (KRON), Outlook Therapeutics (OTLK), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry.
ProPhase Labs vs.
ProPhase Labs (NASDAQ:PRPH) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.
ProPhase Labs has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
ProPhase Labs has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.
9.5% of ProPhase Labs shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 20.7% of ProPhase Labs shares are owned by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ProPhase Labs has a net margin of -217.64% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat ProPhase Labs' return on equity.
In the previous week, Werewolf Therapeutics had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 1 mentions for Werewolf Therapeutics and 0 mentions for ProPhase Labs. Werewolf Therapeutics' average media sentiment score of 0.30 beat ProPhase Labs' score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.
ProPhase Labs presently has a consensus price target of $11.00, indicating a potential upside of 1,706.24%. Werewolf Therapeutics has a consensus price target of $9.33, indicating a potential upside of 586.27%. Given ProPhase Labs' higher possible upside, analysts clearly believe ProPhase Labs is more favorable than Werewolf Therapeutics.
ProPhase Labs received 82 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 69.57% of users gave Werewolf Therapeutics an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote.
Summary
Werewolf Therapeutics beats ProPhase Labs on 9 of the 17 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
This page (NASDAQ:PRPH) was last updated on 1/21/2025 by MarketBeat.com Staff
